Design, synthesis, formulation, and bioevaluation of ZZP-2, a FLT3-ITD inhibitor for the treatment of acute myeloid leukemia
European Journal of Pharmaceutical Sciences · 2026
DOI: 10.1016/j.ejps.2026.107440 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmaceutical Sciences, 2026. Verfasst von Wentao Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi University of Chinese Medicine, Nanchang, 330004, China. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangxi University of Traditional Chinese Medicine.
Abstract (Originalsprache)
FMS-like tyrosine receptor kinase 3 (FLT3) mutations have been recognized as ideal drug discovery targets for the treatment of acute myeloid leukemia (AML). Starting from the reported inhibitor 13v, we rationally designed and synthesized ZZP-2, a pyridine-pyridazine hybrid that displayed single-digit nanomolar IC₅₀ values against FLT3-ITD-positive AML cell lines (MOLM-13 and MV4-11). ZZP-2 suppressed FLT3 autophosphorylation and downstream STAT5, ERK, and AKT signaling in a concentration-dependent manner, exerting antiproliferative effects through multiple mechanisms, including apoptosis induction and cell cycle arrest. However, ZZP-2's aqueous solubility is 95 % drug loading efficiency. After oral administration, the SEDDS formulation increased the ZZP-2 plasma area under the curve (AUC0-∞) by 3.7-fold relative to a suspension formulation in Sprague-Dawley (SD) rats and significantly prolonged survival in MOLM-13-luciferase-bearing NSG mice compared to positive controls sunitinib and gilteritinib, without noticeable toxicity. Our study presents a novel FLT3-ITD inhibitor with high potency and in vivo stability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
- Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, 550004, China.
- Jiangxi University of Chinese Medicine, Nanchang, 330004, China. Electronic address: 19840211@jxutm.edu.cn.
- Jiangxi University of Chinese Medicine, Nanchang, 330004, China. Electronic address: lw9527@yeah.net.
Förderung
- Jiangxi University of Traditional Chinese Medicine
Zitieren
APA
Zhu, W., Qiao, J., Rao, X., Huang, X., Peng, P., Liao, W., Luo, X., & Liu, W. (2026). Design, synthesis, formulation, and bioevaluation of ZZP-2, a FLT3-ITD inhibitor for the treatment of acute myeloid leukemia. European Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ejps.2026.107440
Vancouver
Zhu W, Qiao J, Rao X, Huang X, Peng P, Liao W, et al. Design, synthesis, formulation, and bioevaluation of ZZP-2, a FLT3-ITD inhibitor for the treatment of acute myeloid leukemia. European Journal of Pharmaceutical Sciences. 2026. doi:10.1016/j.ejps.2026.107440
BibTeX
@article{Zhu2026,
author = {Zhu, Wentao and Qiao, Junhao and Rao, Xiaoyong and Huang, Xiuwa and Peng, Peiyu and Liao, Weike and Luo, Xiaojian and Liu, Wei},
title = {Design, synthesis, formulation, and bioevaluation of ZZP-2, a FLT3-ITD inhibitor for the treatment of acute myeloid leukemia},
journal = {European Journal of Pharmaceutical Sciences},
year = {2026},
doi = {10.1016/j.ejps.2026.107440}
}
EUVIMED